Julien Edeline

PU-PH - Full Professor

Université de Rennes 1 Faculté de Médecine

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Julien Edeline is a Full Professor at Université de Rennes 1 Faculté de Médecine in France. His research focuses on hepatocellular carcinoma, biliary tract cancer, and advances in cancer treatment methodologies. Recent publications include studies on innovative therapies such as TCR T-cell therapy and new clinical findings in precision oncology for various cancer types.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (5)

John Bridgewater

UCL Cancer Institute

UNITED KINGDOM

View details

Anthony Turpin

FRANCE

View details

Juan W. Valle

The University of Manchester

UNITED KINGDOM

View details

Mairéad Mcnamara

The University of Manchester

UNITED KINGDOM

View details

Giuseppe Cabibbo

University of Palermo

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Julien Edeline

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Real‐World Outcomes of Atezolizumab–Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma

The MAGIC‐D Prognostic Score: Another Small Step in the Direction of Precision Oncology in Advanced Biliary Tract Cancer

Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma

New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe

First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: the French ACABi GERCOR PRONOBIL cohort

Management of biliary tract cancers in early‐onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort

Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?

Futibatinib dans les cholangiocarcinomes localement avancés ou métastatiques avec fusion ou réarrangement de FGFR2

Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes

<sup>188</sup>Re-SSS Lipiodol Radioembolization in HCC Patients: Results of a Phase 1 Trial (Lip-Re-01 Study)

The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial

Difficulties for providing evidence in hepatocellular carcinoma with Child‐Pugh B liver function

Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?

Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective

Selective Internal Radiation Therapy (Yttrium-90 Glass Microspheres) Combined with Capecitabine in the Neoadjuvant Setting of Operable Intrahepatic CHOlangiocarcinoma: The SIROCHO Trial Design

Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials

Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial

Collaborators (5)

John Bridgewater

Anthony Turpin

Juan W. Valle

Mairéad Mcnamara

Giuseppe Cabibbo

Make your next move.